PHARMAXIS has announced the completion of the first component of its Phase III international trial of Bronchitol, a therapy developed for sufferers of cystic fibrosis.
07/04/2009
ABBOTT has announced the initiation of Mobility, a clinical trial into the safety and efficacy of the Absolute Pro Peripheral Self-Expanding Stent System in patients with iliac artery disease.
16/04/2009
Lonza has entered into an agreement with Micromet for the process development and manufacture of Micromet’s blinatumomab (MT103).
25/11/2009
Australia is falling behind the rest of the world in the take-up of electronic solutions for clinical trials, says Jennie Anderson, CEO of Evado, a clinical software company.
07/12/2009
EMILY Walvoord, M.D., associate professor of clinical pediatrics at the Indiana University School of Medicine says that the trial she coordinated at Riley Hospital for Children has found that inhaled growth hormone (GH) is well tolerated by children with GH deficiency and that this easy-to-use method can, over a one-week period, safely deliver GH to the blood stream.
30/06/2009
MERCK and partner Newron Pharmaceuticals have announced the initiation of their SETTLE1 study designed to evaluate the efficacy and safety of safinamide as add-on therapy to levodopa mid- to late-stage Parkinson’s disease.
08/05/2009
CLINICAL Data has announced the completed sale of Cogenics to Beckman Coulter.
15/04/2009
QUEENSLAND is breaking into one of the world's major markets for clinical trials of medical and pharmaceutical products and equipment.
18/09/2009
Dr Neil Frazer, Prima BioMed's Chief Medical Officer will oversee clinical trials in the US for the company's CVac ovarian cancer vaccine treatment.
27/11/2009
AUSTRALIAN pharmaceutical company Pharmaxis has received encouraging results for its recently completed international Phase III trial of the Bronchitol portable inhaler in patients with cystic fibrosis.
17/06/2009
FERUMOXYTOL, an intravenous form of iron that can be rapidly administered in large doses, can be an effective treatment for iron deficiency in chronic kidney disease (CKD) patients on dialysis, according to a clinical trial appearing in the Clinical Journal of the American Society Nephrology (CJASN).
16/03/2009
A Translational Genomics Research Institute (TGen) team has formed a partnership with Scottsdale Healthcare to conduct the first clinical trials for a drug, NMS-1286937, designed to halt cell division.
15/12/2009
MERCK has announced the results from its 96-week placebo controlled Clarity1 Phase III trial using oral Cladribine Tablets to treat patients with relapsing-remitting multiple sclerosis (MS).
30/04/2009
PHARMACYCLICS has announced it is beginning treatment on patients in a Phase I dose-escalation study to evaluate the safety and tolerability of PCI-32765.
15/04/2009
Initial results from an ongoing US clinical trial sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) demonstrate a robust immune response in healthy pregnant women following just one dose of 2009 H1N1 influenza vaccine.
03/11/2009
AMERICAN pharmaceutical product manufacturer PPD has announced plans to expand its laboratory services into Singapore from mid-2009.
15/01/2009
Roche has announced the results of a phase III trial investigating the use of Avastin (bevacizumab) in combination with docetaxel chemotherapy and prednisone in men with late stage prostate cancer (hormone-refractory / HRPC). The study, known as CALGB 90401, did not meet its primary objective of extending overall survival compared to chemotherapy and prednisone alone.
18/03/2010
THE THERAPEUTIC development program of the clinical drug vilazodone, intended to treat major depression, has entered its final stages.
13/01/2009
THE US Food and Drug Administration (FDA) has released “Influenza: Developing Drugs for Treatment and Prophylaxis,” a draft guidance for industry.
06/03/2009
PEPLIN has announced the initiation of two Phase III clinical trials to confirm the efficacy and safety of PEP005 (ingenol mebutate) Gel for the treatment of actinic (solar) keratoses (AK), a common pre-cancerous skin lesion, when applied to head locations includuing the face and scalp.
10/06/2009